TAMPA, Fla., Sept. 24, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today, Randolph C Read has joined its Business Advisory Board. Oxis is in the process of building a world class Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.

Randolph C. Read has been President and Chief Executive Officer of Nevada Strategic Credit Investments, LLC since 2009. Mr. Read has previously served as President of a variety of other companies, including International Capital Markets Group, Inc. Mr. Read serves on the Boards of Directors of New York REIT, Inc. (as Chairman) a NYSE listed company (NYRT), Healthcare Trust, Inc. (as Chairman), Business Development Corporation of America, and the advisory board of the Flying Food Group, LLC and has previously served on a number of public and private company boards. He has an M.B.A. in Finance from the Wharton Graduate School of the University of Pennsylvania.

"Randy is a vital part of the Oxis plan to be a major biotech company. We are excited to have him on our Advisory Board. Oxis Biotech, Inc. will continue to bring in major biotech assets and surround ourselves with key executives.

"I am very pleased to be joining the Advisory Board of Oxis Biotech, which is attempting to achieve breakthrough developments in treating various forms of cancer that could be of great value to our society," said Mr. Read.

About Oxis Biotech - Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs.  OXIS' lead drug candidate, DT2219ARL is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload.  DT2219ARL simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors.  When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug's cytotoxic payload.  DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.  OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions.  In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.  OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC).  In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.  For more information about Oxis Biotech, please visit http://www.oxis.com.

Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oxis-biotech-inc-announces-appointment-of-randolph-c-read-to-business-advisory-board-300148142.html

SOURCE Oxis Biotech, Inc.